These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 28147318

  • 21. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [Abstract] [Full Text] [Related]

  • 22. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y.
    Drug Des Devel Ther; 2015 Apr; 9():5225-35. PubMed ID: 26396496
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B.
    Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
    [Abstract] [Full Text] [Related]

  • 29. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
    Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.
    Mod Pathol; 2008 Aug 01; 21(8):1002-10. PubMed ID: 18500265
    [Abstract] [Full Text] [Related]

  • 35. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, Shih IM.
    Int J Gynecol Cancer; 2008 Aug 01; 18(3):487-91. PubMed ID: 17692090
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D, Multicentre Italian Trials in Ovarian cancer (MITO) translational group.
    Lancet Oncol; 2016 Aug 01; 17(8):1137-1146. PubMed ID: 27402147
    [Abstract] [Full Text] [Related]

  • 38. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    Eur J Cancer; 2016 Jan 01; 53():51-64. PubMed ID: 26693899
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
    Yildiz Y, Kabadayi G, Yigit S, Kucukzeybek Y, Alacacioglu A, Varol U, Taskaynatan H, Salman T, Oflazoglu U, Akyol M, Tarhan MO.
    J BUON; 2019 Jan 01; 24(4):1549-1554. PubMed ID: 31646807
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.